10-Q: Femasys Faces Liquidity Crisis Amid Nasdaq Delisting Threat

Femasys Inc. reports increased sales and product approvals but warns of substantial doubt about its ability to continue as a going concern, facing Nasdaq delisting and urgent capital needs.

Summary

• Sales increased by 84.8% to $409,268 for the three months ended June 30, 2025, and by 52.4% to $750,532 for the six months ended June 30, 2025, compared to the same periods in 2024.
• Net loss for the six months ended June 30, 2025, increased by 26.5% to $10,482,761, up from $8,284,084 in the prior year period.
• The company had cash and cash equivalents of $3,218,067 as of June 30, 2025, down from $3,451,761 at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $9,117,950, an increase from $8,894,780 in the prior year period.
• Femasys received CE mark certification for the entire FemBloc permanent birth control system in the EU in June 2025 and announced a first commercial order of approximately $400,000 for FemBloc in Spain in August 2025.
• The company obtained Australian and New Zealand regulatory approvals for FemaSeed and FemVue in July 2025.
• Femasys is non-compliant with Nasdaq's Minimum Market Value of Listed Securities ($35.0 million) and Minimum Bid Price ($1.00) requirements, facing potential delisting.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, with current cash expected to fund operations only into early Q4 2025.
• A public offering and concurrent private placement in June 2025 generated gross proceeds of $4.5 million, and an 'Any Market Purchase Agreement' was entered into for up to $10 million in common stock sales until December 31, 2026.

Sentiment

Score: 3

Explanation: While there are positive developments in product approvals, sales growth, and new partnerships, these are heavily overshadowed by critical financial distress. The company faces a 'going concern' warning, significant cash burn, increasing net losses, and immediate Nasdaq delisting threats. The need for continuous capital raises and the high accumulated deficit indicate a precarious financial position and high operational risk.

Positives

• Sales increased significantly by 84.8% for the three months and 52.4% for the six months ended June 30, 2025, driven by FemaSeed and FemVue.
• FemBloc received full CE mark certification under EU Medical Device Regulation (MDR) in June 2025, marking its first global regulatory approval.
• Secured a first commercial order for FemBloc in Spain totaling approximately $400,000, indicating initial market entry success in Europe.
• FemaSeed and FemVue received regulatory approvals in Australia and New Zealand, expanding international market access.
• A new Chief Commercial Officer was appointed on June 17, 2025, to bolster commercialization efforts.
• Formed a partnership with Carolinas Fertility Institute on June 11, 2025, to offer FemaSeed across its multiple locations.
• Successfully completed an underwritten public offering and concurrent private placement in June 2025, raising gross proceeds of $4.5 million.
• Established an 'Any Market Purchase Agreement' with Alumni Capital LP, providing access to up to $10 million in additional equity financing until December 31, 2026.
• Research and development expenses decreased by 28.4% for the three months ended June 30, 2025, due to commercialization of development products and reduced clinical costs.

Negatives

• Net loss for the six months ended June 30, 2025, increased by 26.5% to $10,482,761, indicating growing operational losses.
• The company's cash and cash equivalents decreased to $3,218,067 as of June 30, 2025, from $3,451,761 at December 31, 2024.
• Net cash used in operating activities increased to $9,117,950 for the six months ended June 30, 2025, reflecting a higher cash burn rate.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, as current cash is only sufficient into early Q4 2025.
• The company is non-compliant with Nasdaq's Minimum Market Value of Listed Securities ($35.0 million) and Minimum Bid Price ($1.00) requirements, facing potential delisting by November 17, 2025, and January 12, 2026, respectively.
• Accumulated deficit reached $137,681,018 as of June 30, 2025, highlighting significant historical losses.
• Interest expense increased by 26.8% to $950,949 for the six months ended June 30, 2025, primarily due to non-cash discount amortization related to convertible notes.
• Other expense, net, increased by 244.5% to $1,174,776 for the six months ended June 30, 2025, driven by increased non-cash discount amortization and expenses related to the Any Market Purchase Agreement.
• Convertible notes payable, net, increased to $6,080,813 as of June 30, 2025, and are due in November 2025.

Risks

• Ability to obtain additional financing to fund commercialization, U.S. clinical development of FemBloc, and ongoing operations.
• Ability to pay convertible notes due November 2025 if not converted into common stock.
• Ability to obtain U.S. Food and Drug Administration (FDA) approval for FemBloc permanent birth control.
• Ability to successfully grow sales of FemaSeed intratubal insemination in the U.S. and FemBloc permanent birth control in the European Union.
• Ability to achieve and maintain adequate levels of coverage or reimbursement for FemBloc or any future product candidates.
• Ability to accurately forecast customer demand for products and manage inventory.
• Ability to build, manage, and maintain a direct sales and marketing organization.
• Ability to continue operating as a going concern due to historical losses and anticipated future losses and negative operating cash flows.
• Clinical trials for FemBloc may not demonstrate safety and effectiveness or yield positive results.
• Ability to enroll subjects in the clinical trial for FemBloc in a timely manner.
• Ability to manufacture products in compliance with applicable laws and regulations and oversee third-party suppliers.
• Ability to hire and retain senior management and other highly qualified personnel.
• Impact of FDA or other U.S. or foreign regulatory actions, including healthcare reform measures.
• Timing or likelihood of regulatory filings and approvals or clearances.
• Ability to establish and maintain intellectual property protection and avoid claims of infringement.
• Volatility of the trading price of common stock.
• Risk of delisting from The Nasdaq Capital Market due to non-compliance with Minimum Market Value of Listed Securities ($35.0 million) and Minimum Bid Price ($1.00) requirements.
• Future equity or debt financing may contain terms unfavorable to the company or its stockholders, including dilution.
• Future debt financing may impose restrictive covenants on operations.
• Inability to raise adequate additional capital could force delays, reductions, or termination of development activities and operations, leading to a complete loss of investment.
• Potential impact of the 'One Big Beautiful Bill Act' on the company's estimated annual effective tax rate and cash tax position.

Future Outlook

The company expects net losses to increase over the next few years as it commercializes FemaSeed and FemBloc (in the EU) and advances FemBloc through clinical development for U.S. FDA approval. Current cash and anticipated revenues are expected to fund operations only into early fourth quarter of 2025, necessitating additional financing to sustain operations for the next twelve months, fund FemBloc's U.S. development, and support EU commercialization. Substantial investments are anticipated in ongoing commercialization, the pivotal trial for FemBloc, future product R&D, manufacturing, regulatory affairs, post-market clinical trials, and expanding the sales and marketing organization.

Management Comments

• We are a leading biomedical innovator, addressing significant unmet needs in women's health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products.
• Our suite of products and U.S. product candidate address what we believe are multi-billion dollar global market segments in which there has been little advancement for many years, helping women avoid pharmaceutical solutions, implants and surgery that can be expensive and expose women to harm.
• Although management expects the Company will continue as a going concern, there is no assurance that management's plans will be successful because the availability and amount of such funding are not certain.
• We intend to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split.
• We intend to actively monitor the MVLS of our common stock between now and November 17, 2025, and will consider our available options to regain compliance with the Minimum MVLS Requirement.

Industry Context

Femasys operates in the women's health sector, focusing on addressing significant unmet needs in infertility treatment and permanent birth control. The company positions its products, such as FemaSeed and FemBloc, as disruptive, accessible, in-office alternatives to traditional, often surgical or pharmaceutical, solutions. It highlights the multi-billion dollar global market segments that have seen little advancement, aiming to provide safer, less invasive, and more cost-effective options compared to centuries-old surgical sterilization methods or pharmaceutical solutions that may expose women to harm.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal contingencies requiring accrual or disclosure were reported for the periods presented.
• No currently pending actions against the company were reported.

Related Party Transactions

• In November 2023, the company issued a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc., whose interim CEO, President, and Director, Joshua Silverman, serves on Femasys' board of directors.
• In November 2024, the company paid PharmaCyte $300,000 of accrued interest on the convertible note in common stock, comprising 315,790 shares.
• In conjunction with the June 2025 financing, certain officers and directors purchased 98,040 common shares in the private placement offering at a price of $1.02 per share.
• A family member of the CEO was employed by the company for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders face significant potential dilution from ongoing and future capital raises, as well as the risk of delisting from Nasdaq due to non-compliance with listing standards. There is also a risk of complete loss of investment if the company cannot secure sufficient funding.
• Employees are impacted by the company's financial stability and ability to continue as a going concern, which directly affects job security and the value of share-based compensation.
• Customers' access to FemaSeed, FemVue, and FemBloc products depends on the company's continued operational viability and successful commercialization efforts.
• Creditors, particularly holders of the convertible notes due in November 2025, face uncertainty regarding repayment given the company's liquidity challenges and going concern warning.

Next Steps

• Continue commercialization efforts for FemaSeed in the U.S. and FemBloc in the EU.
• Advance FemBloc through its pivotal clinical trial for U.S. FDA approval.
• Obtain additional financing to fund ongoing operations beyond early Q4 2025.
• Monitor Nasdaq compliance and consider options, including a reverse stock split, to regain compliance with listing requirements.
• Evaluate the full effects of the 'One Big Beautiful Bill Act' on the company's tax position.
• Make substantial investments in research and development for future products, manufacturing, regulatory affairs, and post-market clinical trials.
• Invest in and expand the sales and marketing organization for FemaSeed and FemBloc.

Key Dates

Recommendation

Despite positive developments in product approvals and sales growth, Femasys Inc. faces severe financial distress, including a 'substantial doubt' about its ability to continue as a going concern, a rapidly depleting cash position, and increasing net losses. The company is also non-compliant with Nasdaq's minimum market value and bid price requirements, posing an imminent delisting risk. While recent capital raises provide temporary relief, the ongoing need for significant additional funding, coupled with a large accumulated deficit and near-term convertible note maturity, indicates a highly precarious financial position. The fundamental risks to the company's survival outweigh any operational successes, making it a strong sell.

Keywords

Women's Health, Biomedical, Infertility Treatment, Permanent Birth Control, FemaSeed, FemBloc, FemVue, SEC Filing, 10-Q, Financial Results, Liquidity, Going Concern, Nasdaq Compliance, Medical Devices, Regulatory Approval, Clinical Trials, Capital Raise